The Times Australia
The Times World News

.
The Times Real Estate

.

Alzheimer's drug donanemab has been hailed as a 'turning point' for treatment. But what does it mean for people with the disease?

  • Written by Steve Macfarlane, Head of Clinical Services, Dementia Support Australia, & Associate Professor of Psychiatry, Monash University
Alzheimer's drug donanemab has been hailed as a 'turning point' for treatment. But what does it mean for people with the disease?

Trial results of a new drug to treat Alzheimer’s disease, donanemab, shows it can slow cognitive decline[1] by 35%. The drug has been hailed as a “turning point” in Alzheimer’s treatment.

But as usual, there’s more to the story[2]. The study only included people with early or mild disease, not more advanced symptoms. Donanemab is not a cure for Alzheimer’s. Nor is it 100% safe.

So what did the trial actually find? And how might this drug affect the lives of people with Alzheimer’s disease?

Read more: New Alzheimer’s drug: what you need to know about donanemab’s promising trial results[3]

What is Alzheimer’s disease?

There are more than 100 types of dementia, but Alzheimer’s disease is the most common, accounting for around 70%[4] of cases.

The disease is caused by the accumulation of two proteins: amyloid and tau. Amyloid can accumulate for at least 20 years prior to the onset of symptoms, forming clumps in the brain.

Once symptoms have started and are progressing, tau, a marker of cell damage, also begins to accumulate.

Clinical symptoms progress, on average, over seven to ten years[5] after diagnosis. But in Australia, there is a lag of up to three years[6] from the point at which people first develop symptoms before a diagnosis is typically made.

What have drug treatments aimed to do?

The “amyloid hypothesis[7]”, which suggests amyloid is the key cause of the disease, has driven Alzheimer’s research for more than 25 years.

Multiple drugs targeting amyloid have, however, failed in clinical trials over most of that period, casting doubt on the validity of amyloid as a target – until recently.

Read more: What allegations of Alzheimer's research fraud mean for patients[8]

Our bodies produce antibodies in response to the presence of a foreign invader such as a bacteria or virus. Mimicking the approach taken by our immune systems, scientists have developed antibodies in the lab that recognise amyloid as such an invader.

Specifically targeting amyloid, these drugs are known as monoclonal antibodies. Donanemab is one of three monoclonal antibodies targeting amyloid that have shown various degrees of success in clinical trials in slowing decline in people with early stage disease.

OK so what did the donanemab trial find?

The manufacturer’s clinical trial included 1,736 patients with very mild memory loss due to Alzheimer’s disease, and with early clinical Alzheimer’s disease.

Half received donanemab by intravenous infusion over an 18-month study, the remainder were treated with a placebo (a “dummy” version).

The results were analysed by dividing the study population into two further groups: those with low to intermediate levels of tau; and those with high tau levels (high tau correlates with the presence of more advanced brain cell damage).

Those with low and intermediate tau declined by 35% less than those treated with placebo. About half of the treatment group cleared amyloid from their brains below the threshold used to diagnose the disease, over 12 months of treatment.

The high tau group did far less well.

older couple holding hands with man looking confused
People may be delaying diagnosis because they think nothing can be done. Shutterstock[9]

Participants aged under 75 and those showing only mild cognitive impairment (rather than the full clinical picture of Alzheimer’s disease) had their progression slowed by around 50% over the same period.

Patients were assessed using both cognitive measures and measures of daily function, such as the ability to do personal and household tasks. The results translated into the treatment group showing levels of decline at 18 months that were experienced by the placebo group at 10.5 to 13.6 months, depending on the participant subgroup studied.

Important examples may be that they continue to be able to drive, pay bills, or attend activities outside of the home independently.

But both the treatment and the placebo groups declined overall. In other words, it doesn’t stop the decline, it slows it, in people with mild or early disease.

Read more: Lots of 'breakthroughs', still no cure. Do the new dementia drugs bring us any closer?[10]

What are the downsides?

At least two patients in the trial died from complications of brain swelling caused by donanemab. Around one-quarter of the treatment group showed some degree of swelling, most of which didn’t cause symptoms.

CT scan films displayed Two patients in the study died from complications from brain swelling. Shutterstock[11]

The cost of donanemab will be significant, at US$26,500[12] or around A$39,000 per year.

Donanemab has already been approved by the US Food and Drug Administration. Eli Lilly, the drug’s manufacturer, has applied to the Therapeutic Goods Administration (TGA) for approval for use in Australia.

But TGA approval is only the first step to making the drug available here. A further assessment will determine whether the Pharmaceutical Benefits Scheme subsidises the drug to make it affordable.

It’s likely any PBS listing would restrict the drug’s use to people whose disease state mirrors that of those included in the clinical trial population – people with early symptoms, who have had PET scans showing the presence of amyloid (and low and intermediate tau).

This is not a drug for everyone with Alzheimer’s disease.

Preparing for early detection and treatment

People have tended to delay seeking assessment of their memory symptoms because “nothing can be done anyway”. GPs may have been reluctant to refer to other specialists for assessment for the same reason.

The potential for early treatment means this needs to change. We also need to develop our diagnostic and treatment infrastructure (building the necessary PET scanners and infusion centres) that will be necessary to facilitate timely diagnosis and treatment when the drug does become available locally.

Read more: What is 'sundowning' and why does it happen to many people with dementia?[13]

References

  1. ^ slow cognitive decline (jamanetwork.com)
  2. ^ more to the story (www.nature.com)
  3. ^ New Alzheimer’s drug: what you need to know about donanemab’s promising trial results (theconversation.com)
  4. ^ around 70% (alz-journals.onlinelibrary.wiley.com)
  5. ^ seven to ten years (jamanetwork.com)
  6. ^ up to three years (www.dementia.org.au)
  7. ^ amyloid hypothesis (www.embopress.org)
  8. ^ What allegations of Alzheimer's research fraud mean for patients (theconversation.com)
  9. ^ Shutterstock (www.shutterstock.com)
  10. ^ Lots of 'breakthroughs', still no cure. Do the new dementia drugs bring us any closer? (theconversation.com)
  11. ^ Shutterstock (www.shutterstock.com)
  12. ^ US$26,500 (www.washingtonpost.com)
  13. ^ What is 'sundowning' and why does it happen to many people with dementia? (theconversation.com)

Read more https://theconversation.com/alzheimers-drug-donanemab-has-been-hailed-as-a-turning-point-for-treatment-but-what-does-it-mean-for-people-with-the-disease-209970

The Times Features

How to Protect Your Garden Trees from Wind Damage in Australia

In Australia's expansive landscape, garden trees hold noteworthy significance. They not only enhance the aesthetic appeal of our homes but also play an integral role in the local...

Brisbane Homeowners Warned: Non-Compliant Flexible Hoses Pose High Flood Risk

As a homeowner in Brisbane, when you think of the potential for flood damage to your home, you probably think of weather events. But you should know that there may be a tickin...

Argan Oil-Infused Moroccanoil Shampoo: Nourish and Revitalize Your Hair

Are you ready to transform your hair from dull and lifeless to vibrant and full of life? Look no further than the luxurious embrace of Argan Oil-Infused Moroccanoil Shampoo! In a...

Building A Strong Foundation For Any Structure

Building a home or commercial building can be very exciting. The possibilities are endless and the future is interesting. You can always change aspects of the building to meet the ...

The Role of a Family Dentist: Why Every Household Needs One

source A family dentist isn’t like your regular dentist who may specialise in a particular age group and whom you visit only when something goes wrong. A family dentist takes proa...

Benefits of Getting an Online Medical Certificate

Everyone has experienced it. Rather than taking a break, you drag yourself to the doctor's office, where you have to wait in lengthy lines, and then you have to hurry to get that...

Times Magazine

"Eternal Nurture" by Cara Barilla: A Timeless Collection of Wisdom and Healing

Renowned Sydney-born author and educator Cara Barilla has released her latest book, Eternal Nurture, a profound collection of inspirational quotes designed to support mindfulness, emotional healing, and personal growth. With a deep commitment to ...

How AI-Driven SEO Enhancements Can Improve Headless CMS Content Visibility

Whereas SEO (search engine optimization) is critical in the digital landscape for making connections to content, much of it is still done manually keyword research, metatags, final tweaks at publication requiring a human element that takes extensiv...

Crypto Expert John Fenga Reveals How Blockchain is Revolutionising Charity

One of the most persistent challenges in the charity sector is trust. Donors often wonder whether their contributions are being used effectively or if overhead costs consume a significant portion. Traditional fundraising methods can be opaque, with...

Navigating Parenting Arrangements in Australia: A Legal Guide for Parents

Understanding Parenting Arrangements in Australia. Child custody disputes are often one of the most emotionally charged aspects of separation or divorce. Parents naturally want what is best for their children, but the legal process of determining ...

Blocky Adventures: A Minecraft Movie Celebration for Your Wrist

The Minecraft movie is almost here—and it’s time to get excited! With the film set to hit theaters on April 4, 2025, fans have a brand-new reason to celebrate. To honor the upcoming blockbuster, watchfaces.co has released a special Minecraft-inspir...

The Ultimate Guide to Apple Watch Faces & Trending Wallpapers

In today’s digital world, personalization is everything. Your smartwatch isn’t just a timepiece—it’s an extension of your style. Thanks to innovative third-party developers, customizing your Apple Watch has reached new heights with stunning designs...

LayBy Shopping